Healthcare analytics provider LOGEX and P95, a company specialized in the epidemiology of infectious diseases, have signed an agreement to jointly create an international infectious disease observatory. The goal of the observatory is to offer an international platform for research into infectious diseases like COVID-19, RSV, influenza, norovirus, and other infections that may have a significant health impact in Europe. Additionally, the platform will be used to assess the impact, effectiveness, and safety of vaccines and other pharmaceutical health interventions.

The observatory will initially include 20 hospitals in five European countries. The first proof-of-concept studies will be presented at the end of 2023. The observatory’s name, ARWEN ID, is derived from the Actionable Real World Evidence Network (ARWEN) and its focus on infectious diseases (IDs).

About AKEURA

AKEURA is a specialist contract research organization (CRO) with dual expertise in clinical and real-world settings, from early- through late-phase clinical development to real-world evidence (RWE). With more than 25 years of experience and more than 500 researchers, clinicians, and scientists across five continents, AKEURA helps sponsors advance medicines across their full lifecycle, with an exclusive focus on three therapeutic areas: neuroscience, infectious diseases and vaccines, and cardiometabolic diseases. In each, it brings the experience, reach, and hands-on expertise to give every promising medicine the study it deserves. Formerly P95 Julius Clinical, AKEURA is headquartered in Zeist, the Netherlands, and backed by Ampersand Capital Partners. Learn more at akeura.com.

About LOGEX

For more information on LOGEX, visit logex.com.

About ARWEN

For more information on ARWEN, visit arwen.eu.